Skip to main content
OpenTrials
Completed

NCT Number: NCT05574543

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

The objectives of the study are to evaluate the safety and preliminary efficacy of a single administration of AGA111 for lumbar interbody fusion in patients with degenerative disc disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Degenerative Disc Disease Bone Diseases Intervertebral Disc Degeneration Musculoskeletal Diseases Spinal Diseases

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Beijing Jishuitan Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

A randomized, double-blind, placebo-controlled, phase 1/2 study to evaluate the safety and preliminary efficacy of single administration of AGA111 for lumbar interbody fusion in patients with degenerative disc disease. A total of 60 participants will be enrolled and randomized to placebo, AGA111 0.25 mg, or AGA111 0.5 mg at 1: 1: 1 ratio. All participants will undergo lumbar interbody fusion and receive study treatment during the surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and capable of giving signed informed consent.
  • Male or female, age between 40-80 years.
  • Male or female of childbearing potential must agree to use a highly effective contraception throughout the entire study period, and female subjects must have a negative pregnancy test prior to the randomization.
  • Has degenerative disc disease (DDD) of the lumbosacral(L3-S1) spine that results in back pain, with or without radiating leg pain.
  • Has radiographic evidence (e.g. CT, MRI, x-ray, etc.) of degenerative disc disease.
  • Planning to receive single-level lumbar interbody fusion.
  • Willing and capable of adhering to the protocol and visit schedule.

Exclusion criteria

  • Prior surgical procedure at the involved or adjacent spinal levels.
  • Presence or prior history of inflammatory disease of the spine.
  • Presence or prior history of neoplastic disease of the spine.
  • BMI <18.5 or BMI >35.
  • Documented titanium allergy or intolerance.
  • Presence or prior history of malignancy (except for fully resected basal cell carcinoma of the skin).
  • Presence or history of an uncontrolled, unstable, clinically significant medical condition that, in the opinion of the investigator, could jeopardize or compromise the subject's safety or ability to participate in this study.
  • Active local or systemic infection.
  • Female subject who is pregnant or lactating.
  • Serological evidence of positive human immunodeficiency virus (HIV) antibody.
  • HBsAg positive or HBeAg positive, along with positive HBV DNA test.
  • Serological evidence of HCV antibody, along with HCV RNA > lower limit of detection.
  • Known drug or alcohol abuser.

Treatment and study plan

AGA111

Drug

AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

Placebo

Drug

Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 12 months

    An adverse event (AE) is any untoward medical occurrence in clinical study participant, temporally associated with the use of the investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP.

  2. Number of participants who develop anti-drug antibody to AGA111

    Time frame: Up to 90 days post operation

    Blood samples taken prior to the operation and 5 days, 28 days and 90 days post operation were tested for anti-AGA111 antibodies using an immunoassay method.

Secondary outcomes

  1. Radiographic fusion success

    Time frame: Up to 12 months post operation

    Radiographic fusion success is defined as evidence of continuous bone bridging from the superior to the inferior vertebrae via CT evaluation and no evidence of motion as defined by less than 3mm translational motion and less than 5° in angular motion at the treated level via hyperextension and hyperflexion X-rays.

  2. New Bone formation

    Time frame: Up to 12 months post operation

    New bone formation is defined as the ratio of successful fusion area to the total area in the transverse plane of CT scan.

  3. Oswestry Disability Index (ODI)

    Time frame: Up to 12 months post operation

    The change of point in ODI from baseline.

  4. Pain score through Visual Analogue Scale (VAS)

    Time frame: Up to 12 months post operation

    The change of point in VAS from baseline.

  5. Maximum Concentration (Cmax) of AGA111

    Time frame: 90 minutes before administration, and 30 minutes, 1 hour, 6 hours, and 24 hours post administration.

    Maximum concentration of AGA111 after dosing.

  6. Time to maximum concentration (Tmax) of AGA111

    Time frame: 90 minutes before administration, and 30 minutes, 1 hour, 6 hours, and 24 hours post administration.

    Time to maximum concentration of AGA111 after dosing.

  7. Area under the concentration time curve (AUC)

    Time frame: 90 minutes before administration, and 30 minutes, 1 hour, 6 hours, and 24 hours post administration.

    Definite integral of the curve describing the variation of AGA111 in blood as a function of time.

Sponsors and collaborators

Lead sponsor

Angitia Biopharmaceuticals

Industry

Registry information

Official study title

A Randomized, Double-blinded, Placebo-controlled, Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Single Administration of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Oct 10, 2022
Registry last updated
Oct 10, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.